Receives final USFDA approval for varenicline tablets

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ

Image
ANI Press Release New Delhi
1 min read Last Updated : Jun 21 2023 | 7:44 PM IST
Zydus Lifesciences Limited has announced that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture and market varenicline tablets, 0.5 mg and 1 mg (USRLD: Chantix tablets).
Varenicline tablets are indicated to treat smoking addiction.The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, said the company.
According to IQVIA MAT March 2023, varenicline Tablets, 0.5 mg and 1 mg, had yearly sales of $ 501 million in the United States.
With this, the group now has 374 approvals and has so far filed over 442 ANDAs as of December 31, 2022, since the commencement of the filing process in FY 2003–04.
Earlier in May, Zydus received final approval to manufacture and market ephedrine sulfate injection USP, 50 mg/mL single-dose vials.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anaesthesia.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Zydus LifesciencesAnti-smokingBS Web Reports

First Published: Jun 13 2023 | 5:19 PM IST

Next Story